fluorouracil has been researched along with Hyperammonemia in 39 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 7.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "A case of hyperammonemia induced by chemotherapy, including high-dose fluorouracil(5-FU), for advanced unresectable large intestinal cancer has been reported." | 7.91 | [Case of Hyperammonemia Induced by High-Dose Fluorouracil]. ( Abe, M; Hagiwara, A; Kusakabe, A; Mafune, K; Saito, M, 2019) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 7.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 7.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Hyperammonemia is a rare adverse event of 5-FU." | 6.66 | [Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report]. ( Hirakawa, T; Hirata, K; Iwauchi, T; Kurihara, S; Matsutani, S; Miyamoto, H; Morimoto, J; Nagashima, D; Okada, T; Takeuchi, K; Tanaka, H; Tsujio, G; Uchima, Y; Yamagata, S, 2020) |
| "Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported." | 5.42 | [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis]. ( Iida, T; Isshiki, H; Kaneto, H; Murakami, K; Naganawa, Y; Sasaki, H; Satoh, S; Shimizu, H; Tani, M; Wagatsuma, K, 2015) |
| " We diagnosed 5-fluorouracil (5FU)-induced hyperammonemia." | 4.85 | [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer]. ( Fujita, J; Hirata, T; Kinjyo, F; Kobashikawa, K; Matayoshi, R; Nakamura, M; Ohshiro, M; Takaki, R; Tamura, J, 2009) |
| "Hyperammonemia induced by 5-fluorouracil(5-FU)is known as a rare adverse event, but there are few reports of hyperammonemia occurring during FP(5-FU plus CDDP)treatment for esophageal cancer." | 4.31 | [A Case of Esophageal Cancer with Consciousness Disorder Due to Hyperammonemia during FP Treatment]. ( Chiba, T; Hayashi, M; Iseki, H; Matsui, T; Miura, T; Noguchi, N; Ryotokuji, T; Tsunemi, A; Yamasaki, Y; Yokosuka, T, 2023) |
| "Hyperammonemia cases were more likely to be reported with intravenous fluorouracil than orally administered fluoropyrimidines." | 4.31 | Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. ( Agatsuma, N; Imamaki, H; Nishikawa, Y; Oguro, F; Oura, M, 2023) |
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 3.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "A case of hyperammonemia induced by chemotherapy, including high-dose fluorouracil(5-FU), for advanced unresectable large intestinal cancer has been reported." | 3.91 | [Case of Hyperammonemia Induced by High-Dose Fluorouracil]. ( Abe, M; Hagiwara, A; Kusakabe, A; Mafune, K; Saito, M, 2019) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 3.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 3.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Hyperammonemia is a rare adverse event of 5-FU." | 2.66 | [Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report]. ( Hirakawa, T; Hirata, K; Iwauchi, T; Kurihara, S; Matsutani, S; Miyamoto, H; Morimoto, J; Nagashima, D; Okada, T; Takeuchi, K; Tanaka, H; Tsujio, G; Uchima, Y; Yamagata, S, 2020) |
| " Hyperammonemia induced by 5-FU is relatively rare, with a reported incidence of 5-9%; however, caution is required with high dosage regimens of 5-FU that are currently recommended for colorectal cancer therapy because hyperammonemia is an important side effect." | 2.58 | [A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer]. ( Funahashi, K; Kagami, S; Tamura, A; Yoshino, Y, 2018) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | 1.72 | [Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report]. ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU." | 1.72 | Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment. ( Huitema, ADR; Otten, HM; Verkerk, K, 2022) |
| "5-FU-induced hyperammonaemic encephalopathy started 2 [1-4] days after 5-FU infusion onset." | 1.56 | 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. ( Boige, V; Boilève, A; Chouchana, L; Ducreux, M; Gaboriau, L; Hillaire-Buys, D; Hollebecque, A; Jozwiak, M; Lillo-Le Louët, A; Malka, D; Thomas, L, 2020) |
| "Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported." | 1.42 | [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis]. ( Iida, T; Isshiki, H; Kaneto, H; Murakami, K; Naganawa, Y; Sasaki, H; Satoh, S; Shimizu, H; Tani, M; Wagatsuma, K, 2015) |
| "Although hyperammonemia is known as one of the adverse side effects of 5-FU, a disturbance of consciousness caused by hyperammonemia is not a usual finding." | 1.42 | [A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer]. ( Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S, 2015) |
| "Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m(2), continuous infusion for 5 days q4 weeks." | 1.33 | Intermediate dose 5-fluorouracil-induced encephalopathy. ( Choi, HJ; Chung, HC; Jeung, HC; Kim, YA; Rha, SY; Seong, JS, 2006) |
| "We report here the case of a coma with a favorable outcome following 5FU chemotherapy." | 1.33 | [Coma following chemotherapy: is 5FU implicated? Discussion about on case-report]. ( Heluwaert, F; Hilleret, MN; Martin, C; Martin, D; Santre, C, 2006) |
| "Acute hyperammonemia is a medical emergency for which immediate steps must be taken to minimize permanent brain damage." | 1.32 | Unusual causes of hyperammonemia in the ED. ( Chen, WJ; Shih, FF; Weng, TI, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (20.51) | 29.6817 |
| 2010's | 18 (46.15) | 24.3611 |
| 2020's | 13 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwabara, S | 1 |
| Murakawa, K | 1 |
| Kumagai, K | 1 |
| Takeuchi, Y | 1 |
| Wada, H | 1 |
| Ichinokawa, M | 1 |
| Matsumoto, J | 1 |
| Ono, K | 1 |
| Hirano, S | 1 |
| Furuyama, T | 1 |
| Enjoji, M | 1 |
| Yamato, M | 1 |
| Kondo, I | 1 |
| Hinokida, M | 1 |
| Tatsutomi, Y | 1 |
| Nakazawa, K | 1 |
| Nagayama, K | 1 |
| Ushirokoji, Y | 1 |
| Verkerk, K | 1 |
| Otten, HM | 1 |
| Huitema, ADR | 1 |
| Chiu, YW | 1 |
| Tsui, YK | 1 |
| Shen, HN | 1 |
| Yamasaki, Y | 1 |
| Ryotokuji, T | 1 |
| Matsui, T | 1 |
| Miura, T | 1 |
| Chiba, T | 1 |
| Hayashi, M | 1 |
| Yokosuka, T | 1 |
| Noguchi, N | 1 |
| Tsunemi, A | 1 |
| Iseki, H | 1 |
| Oura, M | 2 |
| Oguro, F | 1 |
| Agatsuma, N | 1 |
| Imamaki, H | 2 |
| Nishikawa, Y | 3 |
| Sawazaki, S | 1 |
| Numata, M | 1 |
| Ju, M | 1 |
| Morita, J | 1 |
| Komori, K | 1 |
| Maezawa, Y | 1 |
| Amano, S | 1 |
| Aoyama, T | 1 |
| Tamagawa, H | 1 |
| Sato, T | 1 |
| Oshima, T | 1 |
| Mushiake, H | 1 |
| Yukawa, N | 1 |
| Masuda, M | 1 |
| Rino, Y | 1 |
| Boilève, A | 3 |
| Thomas, L | 1 |
| Lillo-Le Louët, A | 1 |
| Gaboriau, L | 1 |
| Chouchana, L | 1 |
| Ducreux, M | 2 |
| Malka, D | 2 |
| Boige, V | 1 |
| Hollebecque, A | 2 |
| Hillaire-Buys, D | 1 |
| Jozwiak, M | 3 |
| Fukuda, M | 1 |
| Nabeta, M | 1 |
| Muta, T | 1 |
| Cho, T | 1 |
| Shimamatsu, Y | 1 |
| Shimotsuura, Y | 1 |
| Fukami, K | 1 |
| Takasu, O | 1 |
| Nakamura, T | 1 |
| Shibata, S | 1 |
| Miyatani, Y | 1 |
| Matsubara, H | 1 |
| Ozaki, Y | 1 |
| Ikeda, A | 1 |
| Nakagawa, S | 2 |
| Funakoshi, T | 2 |
| Kataoka, S | 1 |
| Horimatsu, T | 2 |
| Yonezawa, A | 2 |
| Matsubara, T | 2 |
| Yanagita, M | 2 |
| Muto, M | 2 |
| Watanabe, N | 1 |
| Kaizaki, R | 1 |
| Inoue, T | 1 |
| Eguchi, S | 1 |
| Nishiyama, T | 1 |
| Nobori, C | 1 |
| Kunimoto, T | 1 |
| Okazaki, Y | 1 |
| Takatsuka, S | 1 |
| Tsukamoto, T | 2 |
| Nishiguchi, Y | 1 |
| Okada, T | 1 |
| Hirakawa, T | 1 |
| Morimoto, J | 1 |
| Tanaka, H | 1 |
| Miyamoto, H | 1 |
| Tsujio, G | 1 |
| Kurihara, S | 1 |
| Matsutani, S | 1 |
| Nagashima, D | 1 |
| Hirata, K | 1 |
| Iwauchi, T | 1 |
| Yamagata, S | 1 |
| Uchima, Y | 1 |
| Takeuchi, K | 1 |
| Kurokawa, T | 1 |
| Kanemoto, Y | 1 |
| Azuma, Y | 1 |
| Iimura, Y | 1 |
| Kuroda, S | 1 |
| Yazawa, K | 1 |
| Tsurita, G | 1 |
| Tokuyama, S | 1 |
| Fukunaga, M | 1 |
| Konishi, K | 1 |
| Honda, S | 1 |
| Yukimoto, R | 1 |
| Okamoto, A | 1 |
| Saito, A | 1 |
| Okada, K | 1 |
| Ota, H | 1 |
| Yokoyama, S | 1 |
| Miki, H | 1 |
| Kobayashi, K | 1 |
| Osman, D | 1 |
| Marthey, L | 1 |
| Carbonnel, F | 1 |
| Yoshino, Y | 1 |
| Tamura, A | 1 |
| Kagami, S | 1 |
| Funahashi, K | 1 |
| Wicker, C | 1 |
| Verret, B | 1 |
| Leroy, F | 1 |
| Pontoizeau, C | 1 |
| Ottolenghi, C | 1 |
| De Lonlay, P | 1 |
| Hagiwara, A | 1 |
| Abe, M | 1 |
| Mafune, K | 1 |
| Saito, M | 1 |
| Kusakabe, A | 1 |
| Misumi, N | 1 |
| Goto, T | 1 |
| Miyoshi, T | 1 |
| Hiraike, M | 1 |
| Shirasawa, H | 1 |
| Saito, O | 1 |
| Nishino, T | 1 |
| Oudo, M | 1 |
| Okamura, T | 1 |
| Kawachi, Y | 1 |
| Nikkuni, K | 1 |
| Nishimura, A | 1 |
| Makino, S | 1 |
| Kawahara, M | 1 |
| Kitami, C | 1 |
| Hashimoto, Y | 1 |
| Nakano, E | 1 |
| Kuroki, M | 2 |
| Kanno, N | 1 |
| Matsumura, Y | 2 |
| Miura, A | 2 |
| Kikuchi, Y | 2 |
| Hirakawa, H | 2 |
| Barrueco, N | 1 |
| Such Díaz, A | 1 |
| Sáez de la Fuente, J | 1 |
| Escobar, I | 1 |
| Iida, T | 1 |
| Wagatsuma, K | 1 |
| Tani, M | 1 |
| Sasaki, H | 1 |
| Naganawa, Y | 1 |
| Isshiki, H | 1 |
| Murakami, K | 2 |
| Satoh, S | 1 |
| Shimizu, H | 1 |
| Kaneto, H | 1 |
| Thomas, SA | 1 |
| Tomeh, N | 1 |
| Theard, S | 1 |
| Kagawa, Y | 1 |
| Kato, T | 1 |
| Naito, A | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Okishiro, M | 1 |
| Takeno, A | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Tamura, S | 1 |
| Miyamoto, S | 1 |
| Matsubara, K | 1 |
| Teraishi, F | 1 |
| Suzuki, T | 1 |
| Nakamoto, M | 1 |
| Chikuba, A | 1 |
| Nezu, M | 1 |
| Shimamura, H | 1 |
| Watanabe, T | 1 |
| Matsuda, T | 1 |
| Takiue, T | 1 |
| Chikuba, H | 1 |
| Toyokawa, A | 1 |
| Nakajima, T | 1 |
| Inui, K | 1 |
| Yamashita, H | 1 |
| Gon, H | 1 |
| Kanemitsu, K | 1 |
| Tanaka, K | 1 |
| Hamabe, Y | 1 |
| Ishida, T | 1 |
| Nakamura, M | 1 |
| Kobashikawa, K | 1 |
| Tamura, J | 1 |
| Takaki, R | 1 |
| Ohshiro, M | 1 |
| Matayoshi, R | 1 |
| Hirata, T | 1 |
| Kinjyo, F | 1 |
| Fujita, J | 1 |
| Shoji, H | 1 |
| Hiramoto, K | 1 |
| Advani, PP | 1 |
| Fakih, MG | 1 |
| Chang, YY | 1 |
| Lin, JK | 1 |
| Jiang, JK | 1 |
| Martinez-Lapiscina, EH | 1 |
| Erro, ME | 1 |
| Cabada, T | 1 |
| Tuñón, T | 1 |
| Weng, TI | 1 |
| Shih, FF | 1 |
| Chen, WJ | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Widmer, L | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Kim, YA | 1 |
| Chung, HC | 1 |
| Choi, HJ | 1 |
| Rha, SY | 1 |
| Seong, JS | 1 |
| Jeung, HC | 1 |
| Heluwaert, F | 1 |
| Santre, C | 1 |
| Martin, C | 1 |
| Hilleret, MN | 1 |
| Martin, D | 1 |
| Kikuta, S | 1 |
| Asakage, T | 1 |
| Nakao, K | 1 |
| Sugasawa, M | 1 |
| Kubota, A | 1 |
4 reviews available for fluorouracil and Hyperammonemia
| Article | Year |
|---|---|
[Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Consciousness; Esophageal Neoplasms; Fluoroura | 2020 |
[A Case of Hyperammonemia Induced by Chemotherapy with 5-Fluorouracil for Metastatic Colon Cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Hyperam | 2018 |
[A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Chemotherapy, Adjuvant; Colon, Ascen | 2018 |
[A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2009 |
35 other studies available for fluorouracil and Hyperammonemia
| Article | Year |
|---|---|
[Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; Hypera | 2022 |
[A Case of Severe Hyperammonemic Encephalopathy in a Dialysis Patient Following mFOLFOX6 Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Fluorouracil; Humans; Hyperamm | 2021 |
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluoroura | 2022 |
Reversible cerebral edema and herniation caused by 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Brain Edema; Fluorouracil; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
[A Case of Esophageal Cancer with Consciousness Disorder Due to Hyperammonemia during FP Treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Consciousness Disorders; Esophageal Neoplasms; Fluor | 2023 |
Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database.
Topics: Antimetabolites; Antineoplastic Agents; Capecitabine; Drug-Related Side Effects and Adverse Reaction | 2023 |
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousn | 2019 |
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Citric Acid Cycle; Dose-Response Rel | 2020 |
Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report.
Topics: Acidosis, Lactic; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Hyperammonemia with impaired consciousness caused by continuous 5-fluorouracil infusion for colorectal cancer: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Consciousness; Female; F | 2020 |
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Topics: Aged, 80 and over; Ammonia; Antimetabolites, Antineoplastic; beta-Alanine; Drug Administration Sched | 2020 |
[A Case of Disturbance of Consciousness Due to Hyperammonemia during Chemotherapy for Metastasis of Sigmoid Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Consciousness; Female; Fluorouracil; Humans; H | 2020 |
Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consciousness; Female; Fluorouracil; Humans; Hyperam | 2021 |
Drug-induced coma after chemotherapy in intensive care unit: How to make the right diagnosis?
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Coma; Esophageal Neop | 2018 |
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorour | 2019 |
[Case of Hyperammonemia Induced by High-Dose Fluorouracil].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consciousness Disorders; Female; | 2019 |
[Risk factors for hyperammonemia during mFOLFOX6 treatment].
Topics: Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Flu | 2013 |
[A case of hyperammonemic encephalopathy related to 5-FU in an aged patient with recurrent colon cancer treated with FOLFIRI therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Brain Dise | 2013 |
[A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabol | 2013 |
[Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil].
Topics: Adenocarcinoma; Antimetabolites; Fluorouracil; Humans; Hyperammonemia; Lung Neoplasms; Male; Middle | 2014 |
[Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Hyperammonemia; Inte | 2015 |
Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
Topics: Adult; Colorectal Neoplasms; Fluorouracil; Humans; Hyperammonemia; Male | 2015 |
[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colectomy; Consciousness; Fem | 2015 |
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta | 2017 |
[A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabolic; Colonic Neoplasms; | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2009 |
[A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Comb | 2010 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; | 2011 |
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2012 |
5-Fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Neoplasms; Diffusion Magnetic Resonance Imagi | 2012 |
Unusual causes of hyperammonemia in the ED.
Topics: Adult; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Emergency Service, Hospital; Female; | 2004 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
Intermediate dose 5-fluorouracil-induced encephalopathy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasm | 2006 |
[Coma following chemotherapy: is 5FU implicated? Discussion about on case-report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cecal Neoplasms; Cecum; Coma; Fluorouracil; Humans; | 2006 |
The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Topics: Brain Diseases; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Hypera | 2008 |